Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epeleuton in Hypertriglyceridemia and Type 2 Diabetes (Phase IIb)
2020-000065-16Phase 2Completed
- Sponsor
- Afimmune
- Start
- May 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertriglyceridemia and type 2 diabetes mellitus (T2DM) comparing Epeleuton with Placebo (2 arms). Primary endpoint: Percent change in triglycerides from baseline to week 16. Started May 2020; status: completed.
02
Drugs
epeleuton
03
Conditions
hypertriglyceridemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-000065-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000065-16.